Mucociliary clearance enhancement

"Mucociliary clearance enhancement" denotes the therapeutic aim to improve the airway’s natural mucus transport system, primarily by increasing ciliary activity, airway hydration, and/or reducing mucus viscosity. This process is vital in defending the respiratory system from inhaled pathogens, pollutants, and debris. It relies on the coordinated function of multiciliated epithelial cells, adequate ion and water transport (e.g., via CFTR and ENaC), and appropriate mucus production and properties. Multiple pharmacological agents target these pathways, including CFTR modulators (like ivacaftor), mucolytics, and drugs acting on ciliary beat frequency and airway hydration. While individual molecular targets exist within this system (such as CFTR, ENaC, various mucins, and PDEs), “mucociliary clearance enhancement” itself is not a specific molecule, protein, or receptor, but rather a therapeutic class or physiological goal. “Mucociliary clearance enhancement” should not be treated as a canonical target entry; rather, underlying molecular targets relevant to this process include the cystic fibrosis transmembrane conductance regulator (CFTR), epithelial sodium channel (ENaC), various mucin proteins (like MUC5B), and enzymes or channels regulating ciliary function.

Other names

Mucociliary transport enhancementMucociliary escalator enhancement

Enhance ciliary beat frequency; Increase airway surface liquid via ion channel modulation (e.g., CFTR potentiation, ENaC inhibition); Decrease mucus viscosity (mucolysis); Promote fluid secretion from submucosal glands; Reduce sodium absorption to enhance hydration; Anti-inflammatory effects.